In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mayo Medical Laboratories

Division of Mayo Clinic

Latest From Mayo Medical Laboratories

GSK and diaDexus' Rx-Dx Partnership Model

Drug firms don't have a firm grasp of the development of biomarkers or their potential role in clinical decision-making. Nor have they, with few exceptions, looked to the diagnostics industry for help-they've been unwilling to outsource activities related to highly proprietary drug development projects. Moreover, traditionally, drug and diagnostic company alliances haven't fared well because both parties have different value expectations. Small diagnostic companies want biotech-like prices for their contributions; pharma marketers often see diagnostics as limiting to their sales efforts, and certainly something that can take attention away, in a 30-second detail call, from the main event-the higher-priced drug. But an eight-year-old alliance between British drug maker GlaxoSmithKline PLC (GSK) and diaDexus Inc. seems to address these barriers with some novel approaches now starting to bear fruit.
BioPharmaceutical Medical Device

Speaking Out on the Promise of Diagnostics

Emery Stephans, the head of Enterprise Analysis, a consultancy focused on in vitro diagnostics and medical imaging, observes that the in vitro diagnostics industry is slow growing and has only limited resources to spend on development of next-generation products. Nevertheless, he's optimistic about the future, and excited by the promise of pharmacogenomics, analyte specific reagents,and consumerism, which he believes will act as driving forces in diagnostics.
Medical Device Legal Issues

Quest Strengthens Its Hand

Quest Diagnostics' purchase of American Medical Laboratories for $500 million in cash (including assumption of $160 million in debt) is one of a string of acquisitions made by large national laboratories in recent years. While it is by no means Quest's biggest or most strategically critical deal, it gives the nation's largest clinical laboratory a presence in two markets in which it was weak or had no presence, and shores up its rapidly growing esoteric testing business. The deal also eliminates a competitor.

Mayo Medical Ventures

The Mayo Clinic's logo is an expression of its philosophy: three interlocking shields symbolizing a balanced emphasis on medical practice, medical education, and research. Mayo Medical Ventures was created to be involved in those health care activities of the foundation not related to direct patient care--the sale of medical products, publishing and technology commercialization.
See All